We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $293M
Founded date: 2019
Investors 2
| Date | Name | Website |
| 21.05.2022 | OrbiMed | orbimed.co... |
| 20.04.2022 | Atlas Vent... | atlasventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.03.2024 | Series C | $182M | - |
| 21.04.2022 | Series B | $111M | - |
Mentions in press and media 12
| Date | Title | Description |
| 13.08.2024 | Sionna Therapeutics Announces Initiation of Two Phase 1 Clinical Trials of SION-719 and SION-451, in Development for Cystic Fibrosis | - SION-719 and SION-451 are candidates from Sionna's next generation series of highly potent NBD1 stabilizers - BOSTON, Aug. 13, 2024 /PRNewswire/ -- Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly... |
| 16.07.2024 | Sionna Therapeutics Expands Pipeline with Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement with AbbVie | - Two Phase 2 compounds, ABBV-2222 and ABBV-3067, and a Phase 1 compound, ABBV-2851, expand and accelerate Sionna's pipeline of complementary modulators to combine with its novel NBD1 stabilizers – - Previously conducted clinical studies of... |
| 13.03.2024 | Sionna Therapeutics: A Breath of Fresh Air in Cystic Fibrosis Treatment | Sionna Therapeutics, a Boston-based life sciences company, recently secured a whopping $182 million in Series C funding to revolutionize cystic fibrosis (CF) treatment. Led by a team of experts, including CEO Mike Cloonan, Sionna is on a mi... |
| 07.03.2024 | Sionna Therapeutics Raises $182M in Series C Financing | Sionna Therapeutics, a Boston, MA-based clinical-stage life sciences company, raised $182M in Series C funding. The round was led by Enavate Sciences with additional new investors Viking Global Investors and Perceptive Advisors, as well as ... |
| 06.03.2024 | Sionna secures $182M series C to more than double its clinical-stage cystic fibrosis contenders | Sionna Therapeutics has closed a $182 million series C, enough to last through 2026 and more than double the number of cystic fibrosis treatments in clinical development. The midstage raise announced Wednesday is just the latest evidence th... |
| 06.03.2024 | Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis | - Company positioned to have four compounds in clinical trials in 2024 including three NBD1 stabilizers and one ICL4 modulator - - Edd Fleming, M.D., of Enavate Sciences joins company's Board of Directors - BOSTON, March 6, 2024 /PRNewswire... |
| 06.03.2024 | Sionna Therapeutics Announces $182 Million Series C | BOSTON, MA, Sionna Therapeutics, a clinical-stage life sciences company, announced the closing of a $182 million Series C financing to support the clinical development. >> Click here for more funding data on Sionna Therapeutics &g... |
| 21.04.2022 | Sionna Therapeutics Raises $111M in Series B Financing | Sionna Therapeutics, a Boston, MA-based life sciences company developing differentiated treatments for cystic fibrosis (CF), closed a $111m Series B financing. The round was led by OrbiMed with participation from funds advised by T. Rowe Pr... |
| 20.04.2022 | Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis | - |
| 19.04.2022 | Sionna unveils with $111M series B to pursue quest for 'holy grail' cystic fibrosis target | After spending more than two years in stealth mode, Sionna Therapeutics is unveiling with $111 million in series B funds to catapult its cystic fibrosis pipeline and take on market leader Vertex Pharmaceuticals. Having raised roughly $150 m... |
Show more